{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T23:08:19Z","timestamp":1778454499216,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":84,"publisher":"Springer US","isbn-type":[{"value":"9781071650363","type":"print"},{"value":"9781071650370","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5037-0_16","type":"book-chapter","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:10:15Z","timestamp":1778451015000},"page":"223-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Development of T-Cell Bispecific Antibodies: Review, Challenges, and Prospective Solutions in Solid Tumor"],"prefix":"10.1007","author":[{"given":"Chika","family":"Ogami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"12","key":"16_CR1","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941\u20134944. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0547","journal-title":"Cancer Res"},{"issue":"7","key":"16_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann RE, Brinkmann U (2015) Bispecific antibodies. Drug Discov Today 20(7):838\u2013847. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008","journal-title":"Drug Discov Today"},{"issue":"9","key":"16_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"5","key":"16_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"1","key":"16_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","volume":"10","author":"S Dalle","year":"2011","unstructured":"Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C (2011) Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 10(1):178\u2013185. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0385","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"16_CR6","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC (2019) B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129(6):2210\u20132221. https:\/\/doi.org\/10.1172\/JCI126397","journal-title":"J Clin Invest"},{"issue":"7655","key":"16_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Riviere I, Riddell S (2017) Therapeutic T cell engineering. Nature 545(7655):423\u2013431. https:\/\/doi.org\/10.1038\/nature22395","journal-title":"Nature"},{"issue":"6382","key":"16_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"6382","key":"16_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"issue":"10","key":"16_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, Zheng W, Lu Y, Zhang W, Bei Y, Shen P (2019) Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer 121(10):837\u2013845. https:\/\/doi.org\/10.1038\/s41416-019-0578-3","journal-title":"Br J Cancer"},{"issue":"6","key":"16_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss\u00a0SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"issue":"17","key":"16_CR12","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17):2625\u20132635. https:\/\/doi.org\/10.1182\/blood-2013-11-492231","journal-title":"Blood"},{"issue":"6","key":"16_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker\u00a0AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"issue":"8","key":"16_CR14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15(8):1145\u20131154. https:\/\/doi.org\/10.1517\/14712598.2015.1046430","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"16_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/CJI.0b013e3181a1c097","volume":"32","author":"M Amann","year":"2009","unstructured":"Amann M, D\u2019Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Munz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M (2009) Antitumor activity of an EpCAM\/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 32(5):452\u2013464. https:\/\/doi.org\/10.1097\/CJI.0b013e3181a1c097","journal-title":"J Immunother"},{"issue":"5","key":"16_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H (2022) T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol 34(5):552\u2013558. https:\/\/doi.org\/10.1097\/CCO.0000000000000869","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"16_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Grullich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Docke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC (2021) Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13(2):125\u2013141. https:\/\/doi.org\/10.2217\/imt-2020-0256","journal-title":"Immunotherapy"},{"issue":"3","key":"16_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","volume":"21","author":"EA Lim","year":"2023","unstructured":"Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR (2023) Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 21(3):366\u2013375. https:\/\/doi.org\/10.1016\/j.clgc.2023.02.010","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"16_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","volume":"75","author":"M Mau-Sorensen","year":"2015","unstructured":"Mau-Sorensen M, Dittrich C, Dienstmann R, Lassen U, Buchler W, Martinius H, Tabernero J (2015) A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol 75(5):1065\u20131073. https:\/\/doi.org\/10.1007\/s00280-015-2728-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"16_CR20","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.18632\/oncotarget.8574","volume":"7","author":"J Borlak","year":"2016","unstructured":"Borlak J, Langer F, Spanel R, Schondorfer G, Dittrich C (2016) Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcgamma receptors. Oncotarget 7(19):28059\u201328074. https:\/\/doi.org\/10.18632\/oncotarget.8574","journal-title":"Oncotarget"},{"key":"16_CR21","doi-asserted-by":"publisher","unstructured":"Kamakura D, Asano R, Yasunaga M (2021) T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity. Pharmaceuticals (Basel) 14(11). https:\/\/doi.org\/10.3390\/ph14111172","DOI":"10.3390\/ph14111172"},{"issue":"10396","key":"16_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S (2023) T-cell-engaging bispecific antibodies in cancer. Lancet 402(10396):142\u2013158. https:\/\/doi.org\/10.1016\/S0140-6736(23)00521-4","journal-title":"Lancet"},{"key":"16_CR23","doi-asserted-by":"publisher","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T (2021) Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers (Basel) 13(2). https:\/\/doi.org\/10.3390\/cancers13020287","DOI":"10.3390\/cancers13020287"},{"issue":"1","key":"16_CR24","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15(1):2181016. https:\/\/doi.org\/10.1080\/19420862.2023.2181016","journal-title":"MAbs"},{"issue":"1","key":"16_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, Kochanek M, Boll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J\u00a0Immunother Cancer 6(1):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"issue":"8","key":"16_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster\u00a0SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah\u00a0CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065. https:\/\/doi.org\/10.1016\/S1470-2045(22)00335-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"16_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1159\/000525835","volume":"145","author":"H Goto","year":"2022","unstructured":"Goto H, Ogawa C, Iida H, Horibe K, Oh I, Takada S, Maeda Y, Minami H, Nakashima Y, Morris JD, Kormany W, Chen Y, Miyamoto T (2022) Safety and efficacy of blinatumomab in Japanese adult and pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: final results from an expansion cohort. Acta Haematol 145(6):592\u2013602. https:\/\/doi.org\/10.1159\/000525835","journal-title":"Acta Haematol"},{"issue":"18","key":"16_CR28","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martinez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Broske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umana P, Moore T, Weisser M, Dickinson MJ (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959\u20131970. https:\/\/doi.org\/10.1200\/JCO.20.03175","journal-title":"J Clin Oncol"},{"issue":"8","key":"16_CR29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janat-Amsbury MM, Eggert T, Tran B (2024) A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin Cancer Res 30(8):1488\u20131500. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2978","journal-title":"Clin Cancer Res"},{"issue":"6","key":"16_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36(6):458\u2013467. https:\/\/doi.org\/10.1016\/j.ctrv.2010.03.001","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"16_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","volume":"119","author":"M Knodler","year":"2018","unstructured":"Knodler M, Korfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F (2018) Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer 119(3):296\u2013302. https:\/\/doi.org\/10.1038\/s41416-018-0150-6","journal-title":"Br J Cancer"},{"issue":"8","key":"16_CR32","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bjc.2014.443","volume":"111","author":"J Sehouli","year":"2014","unstructured":"Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Brandt B, Chekerov R (2014) Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. Br J Cancer 111(8):1519\u20131525. https:\/\/doi.org\/10.1038\/bjc.2014.443","journal-title":"Br J Cancer"},{"issue":"6","key":"16_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","volume":"69","author":"P Ruf","year":"2010","unstructured":"Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 69(6):617\u2013625. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03635.x","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"16_CR34","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","volume":"126","author":"H Einsele","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM (2020) The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126(14):3192\u20133201. https:\/\/doi.org\/10.1002\/cncr.32909","journal-title":"Cancer"},{"key":"16_CR35","doi-asserted-by":"publisher","unstructured":"Ramdani Y, Lamamy J, Watier H, Gouilleux-Gruart V (2022) Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review. Int J Mol Sci 23(17). https:\/\/doi.org\/10.3390\/ijms23179604","DOI":"10.3390\/ijms23179604"},{"issue":"3","key":"16_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M (2015) Blinatumomab: first global approval. Drugs 75(3):321\u2013327. https:\/\/doi.org\/10.1007\/s40265-015-0356-3","journal-title":"Drugs"},{"issue":"7","key":"16_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC (2020) T cell-engaging therapies \u2013 BiTEs and beyond. Nat Rev Clin Oncol 17(7):418\u2013434. https:\/\/doi.org\/10.1038\/s41571-020-0347-5","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"16_CR38","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F, Homann O, Friedrich M, Pearson JT, Raum T, Yang Y, Caenepeel S, Stevens J, Beltran PJ, Canon J, Coxon A, Bailis JM, Hughes PE (2021) AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res 27(5):1526\u20131537. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2845","journal-title":"Clin Cancer Res"},{"issue":"16","key":"16_CR39","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK (2023) Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol 41(16):2893\u20132903. https:\/\/doi.org\/10.1200\/JCO.22.02823","journal-title":"J Clin Oncol"},{"key":"16_CR40","doi-asserted-by":"publisher","unstructured":"Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai\u00a0M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi\u00a0M, Endo M, Harada A, Frings\u00a0W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa\u00a0T, Tsushima T, Mutoh H, Nishito Y, Takahashi\u00a0M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J (2017) An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med 9(410). https:\/\/doi.org\/10.1126\/scitranslmed.aal4291","DOI":"10.1126\/scitranslmed.aal4291"},{"issue":"17","key":"16_CR41","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1158\/1078-0432.CCR-15-2622","volume":"22","author":"S Lehmann","year":"2016","unstructured":"Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M (2016) In vivo fluorescence imaging of the activity of CEA TCB, a novel T-cell bispecific antibody, reveals highly specific tumor targeting and fast induction of T-cell-mediated tumor killing. Clin Cancer Res 22(17):4417\u20134427. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2622","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16_CR42","doi-asserted-by":"publisher","first-page":"1850395","DOI":"10.1080\/19420862.2020.1850395","volume":"13","author":"AR Root","year":"2021","unstructured":"Root AR, Guntas G, Katragadda M, Apgar JR, Narula J, Chang CS, Hanscom S, McKenna M, Wade J, Meade C, Ma W, Guo Y, Liu Y, Duan\u00a0W, Hendershot C, King AC, Zhang Y, Sousa E, Tam A, Benard S, Yang H, Kelleher K, Jin F, Piche-Nicholas N, Keating SE, Narciandi\u00a0F, Lawrence-Henderson R, Arai M, Stochaj WR, Svenson K, Mosyak L, Lam K, Francis C, Marquette K, Wroblewska L, Zhu\u00a0HL, Sheehan AD, LaVallie ER, D\u2019Antona\u00a0AM, Betts A, King L, Rosfjord E, Cunningham O, Lin L, Sapra P, Tchistiakova L, Mathur D, Bloom L (2021) Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs 13(1):1850395. https:\/\/doi.org\/10.1080\/19420862.2020.1850395","journal-title":"MAbs"},{"issue":"1","key":"16_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s13046-019-1354-1","volume":"38","author":"S Yu","year":"2019","unstructured":"Yu S, Zhang J, Yan Y, Yao X, Fang L, Xiong H, Liu Y, Chu Q, Zhou P, Wu K (2019) A novel asymmetrical anti-HER2\/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res 38(1):355. https:\/\/doi.org\/10.1186\/s13046-019-1354-1","journal-title":"J Exp Clin Cancer Res"},{"key":"16_CR44","doi-asserted-by":"publisher","unstructured":"First Drug Approved for Rare Eye Cancer (2022) Cancer Discov 12(4):879\u2013880. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2022-0009","DOI":"10.1158\/2159-8290.CD-NB2022-0009"},{"issue":"8","key":"16_CR45","doi-asserted-by":"publisher","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","volume":"7","author":"M Kebenko","year":"2018","unstructured":"Kebenko M, Goebeler ME, Wolf M, Hasenburg\u00a0A, Seggewiss-Bernhardt R, Ritter\u00a0B, Rautenberg\u00a0B, Atanackovic D, Kratzer A, Rottman JB, Friedrich\u00a0M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W (2018) A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors. Oncoimmunology 7(8):e1450710. https:\/\/doi.org\/10.1080\/2162402X.2018.1450710","journal-title":"Oncoimmunology"},{"issue":"1","key":"16_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48479-8","volume":"15","author":"NH Segal","year":"2024","unstructured":"Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argiles G (2024) CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nat Commun 15(1), 4091. https:\/\/doi.org\/10.1038\/s41467-024-48479-8","journal-title":"Nat Commun"},{"issue":"28","key":"16_CR47","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1073\/pnas.1000976107","volume":"107","author":"R Lutterbuese","year":"2010","unstructured":"Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P (2010) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 107(28):12605\u201312610. https:\/\/doi.org\/10.1073\/pnas.1000976107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16_CR48","doi-asserted-by":"publisher","unstructured":"Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, Johnston J, Low J, Ybarra R, Slaga D, Yang J, Ovacik M, Dybdal NO, Totpal K, Junttila MR, Ellerman D, Lee G, Dennis MS, Prell R, Junttila TT (2020) Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody. JCI Insight 5(7). https:\/\/doi.org\/10.1172\/jci.insight.133757","DOI":"10.1172\/jci.insight.133757"},{"issue":"1","key":"16_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavare R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D\u2019Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E (2021) Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep 11(1):14397. https:\/\/doi.org\/10.1038\/s41598-021-93842-0","journal-title":"Sci Rep"},{"issue":"4","key":"16_CR50","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.Mct-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, Lin K, Joseph SB, Dennis MS, Prabhu S, Junttila\u00a0TT, Boswell CA (2018) Relative target affinities of T-cell\u2013dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther 17(4):776\u2013785. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0657","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"16_CR51","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","volume":"22","author":"M Bacac","year":"2016","unstructured":"Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer\u00a0T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umana P (2016) A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res 22(13):3286\u20133297. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1696","journal-title":"Clin Cancer Res"},{"key":"16_CR52","doi-asserted-by":"publisher","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, Trinklein ND, Buelow R, Buelow B, Fong L, Dalvi P (2021) Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer 9(6). https:\/\/doi.org\/10.1136\/jitc-2021-002488","DOI":"10.1136\/jitc-2021-002488"},{"key":"16_CR53","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M (2022) Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 13:1035276. https:\/\/doi.org\/10.3389\/fimmu.2022.1035276","journal-title":"Front Immunol"},{"issue":"17","key":"16_CR54","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T (2022) Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol 40(17):1939\u20131948. https:\/\/doi.org\/10.1200\/JCO.21.01805","journal-title":"J Clin Oncol"},{"issue":"4","key":"16_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-020-00450-3","volume":"22","author":"H Ma","year":"2020","unstructured":"Ma H, Wang H, Sove RJ, Jafarnejad M, Tsai CH, Wang J, Giragossian C, Popel AS (2020) A quantitative systems pharmacology model of T cell engager applied to solid tumor. AAPS J 22(4):85. https:\/\/doi.org\/10.1208\/s12248-020-00450-3","journal-title":"AAPS J"},{"issue":"11","key":"16_CR56","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/psp4.12928","volume":"12","author":"J Weddell","year":"2023","unstructured":"Weddell J (2023) Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT Pharmacometrics Syst Pharmacol 12(11):1726\u20131737. https:\/\/doi.org\/10.1002\/psp4.12928","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"16_CR57","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.1961","volume":"108","author":"A Betts","year":"2020","unstructured":"Betts A, van der Graaf PH (2020) Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther 108(3):528\u2013541. https:\/\/doi.org\/10.1002\/cpt.1961","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"16_CR58","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 24(6):e255\u2013e269. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6","journal-title":"Lancet Oncol"},{"key":"16_CR59","doi-asserted-by":"publisher","unstructured":"Balendran S, Tam C, Ku M (2023) T-cell engaging antibodies in diffuse large B cell lymphoma-an update. J Clin Med 12(21). https:\/\/doi.org\/10.3390\/jcm12216737","DOI":"10.3390\/jcm12216737"},{"issue":"20","key":"16_CR60","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133(20):2212\u20132221. https:\/\/doi.org\/10.1182\/blood-2018-12-893396","journal-title":"Blood"},{"key":"16_CR61","doi-asserted-by":"publisher","unstructured":"Rees JH (2022) Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In: Kroger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (eds) The EBMT\/EHA CAR-T cell handbook. Cham (CH), pp 141\u2013145. https:\/\/doi.org\/10.1007\/978-3-030-94353-0_27","DOI":"10.1007\/978-3-030-94353-0_27"},{"key":"16_CR62","doi-asserted-by":"publisher","first-page":"1273507","DOI":"10.3389\/fimmu.2023.1273507","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, Lou X, Yu L, Feng W (2023) Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol 14:1273507. https:\/\/doi.org\/10.3389\/fimmu.2023.1273507","journal-title":"Front Immunol"},{"issue":"10","key":"16_CR63","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"16_CR64","doi-asserted-by":"publisher","unstructured":"Kauer J, Horner S, Osburg L, Muller S, Marklin M, Heitmann JS, Zekri L, Rammensee HG, Salih HR, Jung G (2020) Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer 8(1). https:\/\/doi.org\/10.1136\/jitc-2020-000621","DOI":"10.1136\/jitc-2020-000621"},{"key":"16_CR65","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A Geraud","year":"2024","unstructured":"Geraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM (2024) Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer 205:114075. https:\/\/doi.org\/10.1016\/j.ejca.2024.114075","journal-title":"Eur J Cancer"},{"issue":"13","key":"16_CR66","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"TG Martin","year":"2023","unstructured":"Martin TG, Mateos MV, Nooka A, Banerjee A, Kobos R, Pei L, Qi M, Verona R, Doyle M, Smit J, Sun W, Trancucci D, Uhlar C, van de Donk N, Rodriguez C (2023) Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma. Cancer 129(13):2035\u20132046. https:\/\/doi.org\/10.1002\/cncr.34756","journal-title":"Cancer"},{"key":"16_CR67","doi-asserted-by":"publisher","first-page":"e75458a75458","DOI":"10.1097\/01.HS9.0000970688.75458.a8","volume":"7","author":"M Maria-Victoria","year":"2023","unstructured":"Maria-Victoria M, Bahlis NJB, Andrew S, Kaedbey RK, Paula R, Harrison SH, Wong CW, Goodman GG, Rin N, Voleak C, Cooper JC, Suzanne T (2023) P946: Tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (RRMM) who receive cevostamab. HemaSphere 7:e75458a75458. https:\/\/doi.org\/10.1097\/01.HS9.0000970688.75458.a8","journal-title":"HemaSphere"},{"issue":"6","key":"16_CR68","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","volume":"132","author":"A Nellan","year":"2018","unstructured":"Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, Warren KE (2018) Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in Rhesus macaques. Blood 132(6):662\u2013666. https:\/\/doi.org\/10.1182\/blood-2018-05-846428","journal-title":"Blood"},{"issue":"3","key":"16_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J (2021) Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 56(3):552\u2013566. https:\/\/doi.org\/10.1038\/s41409-020-01134-4","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"16_CR70","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"16_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/CJI.0000000000000512","volume":"47","author":"C Kamperschroer","year":"2024","unstructured":"Kamperschroer C, Guffroy M, Shen A, Dokmanovich M, Stubbs M, O\u2019Donnell LM (2024) Nonclinical investigation of cytokine mitigation strategies for T-cell-engaging bispecifics in the cynomolgus macaque. J\u00a0Immunother 47(5):160\u2013171. https:\/\/doi.org\/10.1097\/CJI.0000000000000512","journal-title":"J Immunother"},{"issue":"24","key":"16_CR72","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wrobel T, Offner F, Trneny M, Wu SJ, Cartron\u00a0G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon\u00a0M, Clark E, Humphrey K, Hutchings M (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med \u00a0387(24):2220\u20132231. https:\/\/doi.org\/10.1056\/NEJMoa2206913","journal-title":"N Engl J Med"},{"key":"16_CR73","doi-asserted-by":"publisher","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno\u00a0JN, Callahan C, Davila ML, Diamonte C, Dietrich\u00a0J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee\u00a0DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001511","DOI":"10.1136\/jitc-2020-001511"},{"issue":"2","key":"16_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Kohl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kroger N (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE. Haematologica 105(2):297\u2013316. https:\/\/doi.org\/10.3324\/haematol.2019.229781","journal-title":"Haematologica"},{"issue":"4","key":"16_CR75","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/10781552221140320","volume":"29","author":"BC Lipe","year":"2023","unstructured":"Lipe BC, Renaud T (2023) Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting. J Oncol Pharm Pract 29(4):1006\u20131010. https:\/\/doi.org\/10.1177\/10781552221140320","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"16_CR76","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24(6):739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nat Med"},{"key":"16_CR77","doi-asserted-by":"publisher","unstructured":"Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O\u2019Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ (2022) Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 10(1). https:\/\/doi.org\/10.1136\/jitc-2021-003847","DOI":"10.1136\/jitc-2021-003847"},{"issue":"7","key":"16_CR78","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, Lopez-Corral L, Hernani R, Ortiz-Maldonado V, Martinez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J (2023) Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther 29(7):430\u2013437. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.001","journal-title":"Transplant Cell Ther"},{"key":"16_CR79","doi-asserted-by":"publisher","unstructured":"Salvaris R, Ong J, Gregory GP (2021) Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med 11(5). https:\/\/doi.org\/10.3390\/jpm11050355","DOI":"10.3390\/jpm11050355"},{"key":"16_CR80","doi-asserted-by":"publisher","first-page":"115986","DOI":"10.1016\/j.taap.2022.115986","volume":"441","author":"Y Iwata","year":"2022","unstructured":"Iwata Y, Narushima Y, Harada A, Mishima M (2022) Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state\u00a0in T cells. Toxicol Appl Pharmacol 441:115986. https:\/\/doi.org\/10.1016\/j.taap.2022.115986","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"16_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S (2020) Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl 6(1):28. https:\/\/doi.org\/10.1038\/s41540-020-00145-7","journal-title":"NPJ Syst Biol Appl"},{"issue":"6","key":"16_CR82","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S (2022) Tebentafusp: first approval. Drugs\u00a082(6):703\u2013710. https:\/\/doi.org\/10.1007\/s40265-022-01704-4","journal-title":"Drugs"},{"issue":"8","key":"16_CR83","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S (2024) Tarlatamab: first approval. Drugs 84(8):995\u20131003. https:\/\/doi.org\/10.1007\/s40265-024-02070-z","journal-title":"Drugs"},{"issue":"1","key":"16_CR84","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ (2024) Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate. Cancer: results from dose exploration in a first-in-human study. Cancer Discov 14(1):76\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0964","journal-title":"Cancer Discov"}],"container-title":["Methods in Molecular Biology","Bispecific Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5037-0_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:10:16Z","timestamp":1778451016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5037-0_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650363","9781071650370"],"references-count":84,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5037-0_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}